Photo from Yüksel Ürün/X
Dec 6, 2023, 13:54
Yüksel Ürün: The TALAPRO-2 trial shows a promising combo of talazoparib and enzalutamide for metastatic castration-resistant prostate cancer with HRR gene alterations
Yüksel Ürüna, Professor at Ankara University School of Medicine, shared on X/Twitter:
“The TALAPRO-2 trial shows a promising combo of talazoparib and enzalutamide for mCRPC with HRR gene alterations.
Key findings:
- Median progression-free survival not reached in talazoparib group vs. 13.8 months in control, HR 0.45
- Overall survival data remain immature, early signs are hopeful! HR 0.69
- Patients with BRCA1/BRCA2 alterations had an 80% lower risk of radiographic progression or death HR, 0.20.”
For the article click here.
Source: Yüksel Ürün/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Dec 3, 2024, 13:26
Dec 3, 2024, 11:53
Dec 3, 2024, 11:50
Dec 3, 2024, 11:43